In late 2025, the pharmaceutical landscape saw a strategic shift as Emmaus Life Sciences officially transferred the commercial rights of its flagship product to a partner in the North American region.
Agreement terms and market scope Under the licensing agreement, NeoImmuneTech (NIT) has secured exclusive rights to distribute, market, and sell Endari—an L-glutamine oral powder—and its generic equivalents in the United States, its territories, and Canada. In exchange, Emmaus is entitled to an upfront payment and recurring royalties based on NIT’s product sales performance in these designated regions.
Product indications and global footprint Endari is indicated to mitigate acute complications of sickle cell disease in both adults and pediatric patients aged five and older. The therapy is currently authorized for sale in several nations, including the US, Israel, and multiple Middle Eastern countries (Kuwait, Bahrain, Qatar, Oman, and the UAE). It is also available through early access programs in France and the Netherlands, with pending regulatory action in Saudi Arabia.
Strategic perspectives from leadership
-
Emmaus: The company’s leadership views this as a strategic reassessment to maximize global brand value. While the US remains a steady revenue stream, Emmaus intends to pivot its focus toward high-growth potential regions like the Middle East, Europe, and Brazil.
-
NIT: Acquiring an FDA-approved therapy provides the firm with a foundation for direct commercialization. The infrastructure built for Endari—including distribution and reimbursement networks—is expected to create synergies for the future launch of NIT’s proprietary pipeline products.
Source: https://www.worldpharmaceuticals.net/news/emmaus-nit-sign-endari-distribution-agreement/